Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis

被引：0
|
作者：
Jörg Tamihardja
Max Schortmann
Ingulf Lawrenz
Stefan Weick
Klaus Bratengeier
Michael Flentje
Matthias Guckenberger
Bülent Polat
机构：
[1] University Hospital Wuerzburg,Department of Radiation Oncology
[2] University of Wuerzburg,Department of Radiation Oncology
[3] University Hospital Zurich,undefined
[4] University of Zurich,undefined
来源：
Strahlentherapie und Onkologie | 2021年 / 197卷
关键词：
Simultaneous integrated boost; Cone beam CT; Hypofractionation; Intensity-modulated radiation therapy; Image-guided radiation therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：124 / 132
页数：8
相关论文
共 50 条
  • [1] Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis
    Tamihardja, Joerg
    Schortmann, Max
    Lawrenz, Ingulf
    Weick, Stefan
    Bratengeier, Klaus
    Flentje, Michael
    Guckenberger, Matthias
    Polat, Buelent
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (02) : 124 - 132
  • [2] Moderately hypofractionated radiotherapy for localized prostate cancer Long-term outcome using IMRT and volumetric IGRT
    Guckenberger, M.
    Lawrenz, I.
    Flentje, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2014, 190 (01) : 48 - 53
  • [3] Toxicity and outcome in moderately hypofractionated radiotherapy for 590 prostate cancer patients
    Maucieri, A.
    Jereczek-Fossa, B. A.
    Ciardo, D.
    Fodor, C.
    Maisonneuve, P.
    Surgo, A.
    Volpe, S.
    Marvaso, G.
    Vavassori, A.
    Viola, A.
    Musi, G.
    De Cobelli, O.
    Orecchia, R.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S384 - S385
  • [4] Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer
    Teh, Bin S.
    Lewis, Gary D.
    Mai, Weiyuan
    Pino, Ramiro
    Ishiyama, Hiromichi
    Butler, Edward Brian
    CANCER COMMUNICATIONS, 2018, 38
  • [5] Accelerated hypofractionated radiotherapy in men with localized prostate cancer: long-term outcomes
    Galalae, R
    Schultze, J
    Nuernberg, N
    Kohr, P
    RADIOTHERAPY AND ONCOLOGY, 2004, 73 : S403 - S403
  • [6] Long-Term Outcomes of Dose-Escalated Hypofractionated Radiotherapy in Localized Prostate Cancer
    Lazo, Antonio
    de la Torre-Luque, Alejandro
    Arregui, Gregorio
    Rivas, Daniel
    Serradilla, Ana
    Gomez, Joaquin
    Jurado, Francisca
    Isabel Nunez, Maria
    Lopez, Escarlata
    BIOLOGY-BASEL, 2022, 11 (03):
  • [7] Moderate hypofractionated radiotherapy for post-operative treatment of prostate cancer: long-term outcome and pattern of toxicity
    Franzese, Ciro
    Badalamenti, Marco
    Baldaccini, Davide
    D'Agostino, Giuseppe
    Comito, Tiziana
    Franceschini, Davide
    Clerici, Elena
    Navarria, Pierina
    Reggiori, Giacomo
    Tomatis, Stefano
    Scorsetti, Marta
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (02) : 133 - 140
  • [8] Moderate hypofractionated radiotherapy for post-operative treatment of prostate cancer: long-term outcome and pattern of toxicity
    Ciro Franzese
    Marco Badalamenti
    Davide Baldaccini
    Giuseppe D’Agostino
    Tiziana Comito
    Davide Franceschini
    Elena Clerici
    Pierina Navarria
    Giacomo Reggiori
    Stefano Tomatis
    Marta Scorsetti
    Strahlentherapie und Onkologie, 2021, 197 : 133 - 140
  • [9] Long-term outcome of hypofractionated intensity-modulated radiotherapy using TomoTherapy for localized prostate cancer: A retrospective study
    Takakusagi, Yosuke
    Kawamura, Hidemasa
    Okamoto, Masahiko
    Kaminuma, Takuya
    Kubo, Nobuteru
    Mizukami, Tatsuji
    Sato, Hiro
    Onishi, Masahiro
    Ohtake, Nobuaki
    Sekihara, Tetsuo
    Nakano, Takashi
    PLOS ONE, 2019, 14 (02):
  • [10] Moderately Hypofractionated Radiotherapy and Androgen Deprivation Therapy for High-risk Localised Prostate Cancer: Predictors of Long-term Biochemical Control and Toxicity
    Maulik, S.
    Arunsingh, M.
    Arun, B.
    Prasath, S.
    Mallick, I
    CLINICAL ONCOLOGY, 2022, 34 (01) : E52 - E60
12345